A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.

about

Clinical review: bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and management

P2860

Q33750028-C01FD853-39DC-4F3D-96D3-A06B1659FD68

P2860

A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.

Item

http://www.wikidata.org/entity/Q38098889

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.

@en

type

Item

label

A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.

@en

prefLabel

A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.

@en

P1476

A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.

@en

P2093

Chunyu Zeng

http://www.w3.org/2001/XMLSchema#string

Hongyong Wang

http://www.w3.org/2001/XMLSchema#string

Wei Eric Wang

http://www.w3.org/2001/XMLSchema#string

Xukai Wang

http://www.w3.org/2001/XMLSchema#string

P2860

ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment el

Ticlopidine and clopidogrel.

2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiol

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study.

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.

New P2Y(12) inhibitors.

Arterial thrombosis--insidious, unpredictable and deadly.

P2888

s11239-013-0918-8

P304

102-106

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11239-013-0918-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23584598

http://www.w3.org/2001/XMLSchema#string

A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.

about

P2860

P2860

A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698